Novartis

Novartis CEO Says U.S. Plant Gets FDA Clearance

India Revokes Roche Patent in New Blow for Big Pharma

Sanofi Draws Fire Over Cost of MS Drug Lemtrada

ThromboGenics Says Main Drug Cleared for U.S. Launch

Novartis CEO Keen to Keep Dividend, Big M&A Not Likely

Maturing Belgian Biotechs Outshine European Peers

The European Pharmaceuticals Economy at Halftime 2012

Topics • Technology

Stick to Your Strengths with Biosimilars

Showdown for Big Pharma in India's Highest Court

Novartis Drug Afinitor Gets EU Nod for Breast Cancer

U.S. Health Advisers Back Two New Eye Treatments

EU Crisis Piles on Pain for Europe's Drugmakers

Biogen Q2 Profit Up on MS Drug Sales

Novartis on Track despite Bigger Dollar Hit

US Top Court Rules for Glaxo on Overtime Pay

Stada to Seek Deals as Sector Consolidates

Watson, Actavis to Unveil Deal

EU Supports Novartis MS Pill with Stronger Warning

Chasing Cheaper Cancer Drugs

Bayer Sounds Out Debt Market with Eye On Deals

AstraZeneca, Novartis and Sanofi Douse Hopes For New Drugs

Global Pharma to Pump Cash Into Russia

Lonza Sees Growth on Pharma Outsourcing

Novartis Expects Annual Cost Synergies of $350 Million From Alcon Integration

Novartis Posts Higher Q2 Profit

Bayer Loses European Patent For Yasmin

Bidders Emerge For Gen-Probe, Phadia

Pressure On Actelion Rises After Asahi Case Decision

Roche Seen Kicking off Q1 Season With Sales Drop

Merck KGaA Eyes Job Cuts at Drugs Unit

Novartis Eyes Debts, Possible Smaller Buys

Biosimilars Seen as a $3.7 billion Drug Market by 2015

Andre Hoffmann: Roche Will Not Be For Sale

Bayer in U.S. Accused of Discrimination

Roche's Strong Pipeline Leaves Shareholders Optimistic

53 more articles

Top-Feature

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Expert Insights

ADCs for Precision Cancer Therapy

Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.